First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Public ClinicalTrials.gov record NCT01215136. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Study identification
- NCT ID
- NCT01215136
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Matthew Galsky
- Other
- Enrollment
- 36 participants
Conditions and interventions
Interventions
- Everolimus Drug
- Paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2010
- Primary completion
- Apr 23, 2017
- Completion
- Apr 23, 2018
- Last update posted
- Nov 23, 2023
2010 – 2018
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama Hematology Oncology Clinic at Medical West | Birmingham | Alabama | 35294 | — |
| Northwestern University, Robert H. Lurie Comprehensive Cancer Center | Chicago | Illinois | 60611 | — |
| Cancer Care Center of Southern Indiana | Bloomington | Indiana | 47403 | — |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| IU Health Central Indiana Cancer Centers | Indianapolis | Indiana | 46219 | — |
| Metro Health Cancer Care | Wyoming | Michigan | 49519 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68114 | — |
| Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center | New York | New York | 10029 | — |
| MUSC Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| University of Texas Medical Branch | Galveston | Texas | 77555 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01215136, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 23, 2023 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01215136 live on ClinicalTrials.gov.